451 related articles for article (PubMed ID: 15663787)
1. Molecular models of NS3 protease variants of the Hepatitis C virus.
da Silveira NJ; Arcuri HA; Bonalumi CE; de Souza FP; Mello IM; Rahal P; Pinho JR; de Azevedo WF
BMC Struct Biol; 2005 Jan; 5():1. PubMed ID: 15663787
[TBL] [Abstract][Full Text] [Related]
2. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
3. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
Liu D; Wang YS; Gesell JJ; Wyss DF
J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
[TBL] [Abstract][Full Text] [Related]
4. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
5. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
6. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
7. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
[TBL] [Abstract][Full Text] [Related]
8. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
[TBL] [Abstract][Full Text] [Related]
9. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form.
Yan Y; Li Y; Munshi S; Sardana V; Cole JL; Sardana M; Steinkuehler C; Tomei L; De Francesco R; Kuo LC; Chen Z
Protein Sci; 1998 Apr; 7(4):837-47. PubMed ID: 9568891
[TBL] [Abstract][Full Text] [Related]
10. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
De Francesco R; Pessi A; Steinkühler C
Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
[TBL] [Abstract][Full Text] [Related]
11. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
12. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
[TBL] [Abstract][Full Text] [Related]
13. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
Murthy HM; Judge K; DeLucas L; Padmanabhan R
J Mol Biol; 2000 Aug; 301(4):759-67. PubMed ID: 10966782
[TBL] [Abstract][Full Text] [Related]
16. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
Fatima K; Tahir M; Qadri I
Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
[TBL] [Abstract][Full Text] [Related]
17. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
[TBL] [Abstract][Full Text] [Related]
18. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
19. Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
Failla CM; Pizzi E; De Francesco R; Tramontano A
Fold Des; 1996; 1(1):35-42. PubMed ID: 9079362
[TBL] [Abstract][Full Text] [Related]
20. Characterization of mimotopes mimicking an immunodominant conformational epitope on the hepatitis C virus NS3 helicase.
Jolivet-Reynaud C; Adida A; Michel S; Deléage G; Paranhos-Baccala G; Gonin V; Battail-Poirot N; Lacoux X; Rolland D
J Med Virol; 2004 Mar; 72(3):385-95. PubMed ID: 14748062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
